Ypsomed: Q1 Qualitative Update; Off to a strong start

Research evidence excerpt

Ypsomed: Q1 Qualitative Update; Off to a strong start

Deutsche Bank

Research

Rating Company Date

Hold Ypsomed 9 July 2026

Company Update

Europe

Switzerland

Reuters Bloomberg Exchange Ticker Price at 8 Jul 2026 (CHF) 351.20

YPSN.S YPSN SW SWX YPSN

Price Target (CHF) 345.00

Healthcare

436.00 -

Medical Technologies & 52-week range (CHF) 267.00

Services

Q1 Qualitative Update; Off to a strong

Valuation & Risks start

Fynn Scherzler

Takeaway summary Research Analyst

Ypsomed provided a qualitative update for Q1, highlighting a strong start to the +49-69-910-40764

fiscal year, without disclosing any financial details.

Falko Friedrichs

Research Analyst

The company points to strong commercial momentum, with Ypsomed securing 14 +49-69-910-36270

new customer projects during the quarter, above the prior-year quarterly average.

Jan Koch, CFA

Management attributed this to continued demand for large-volume autoinjectors

(YpsoMate 2.25 mL Pro and YpsoMate 5.5 mL), increasing biosimilar launches,

+49-69-910-47428

expansion into new therapeutic areas such as infectious diseases, and early

traction from the recently launched Clear-to-Clinic program. Sachin Gadilingappa

Research Associate

The company also highlighted continued external recognition of its product

innovation, with both YpsoLoop and YpsoMate 5.5 mL receiving industry awards

Price/price relative

during the quarter.

The manufacturing expansion remains on track. Ypsomed is commissioning its 400

first high-capacity YpsoMate production line in Solothurn, while the new fully 300

automated warehouse in Schwerin has been completed. 200

2024 2025 2026

Overall, the update points to continued strong demand for Ypsomed's delivery Ypsomed – (Rebased)

platforms and supports management's growth strategy. While no comments